Benzodiazepines and Risk for Breast Cancer

Use of benzodiazepine and risk of cancer: A meta-analysis of observational studies

“…First, a small portion of the included studies in our analysis adjusted tobacco smoking and alcohol drinking as a confounding factor, both of which are well known important factors for developing cancer. Out of the 22 included studies, only eight studies 8,[17][18][19][20]22,23,29 adjusted tobacco smoking as a confounding factor, and seven studies 8,17,18,20,22,23,29 adjusted alcohol intake as a confounding factor. Thus, we are unable to exclude the confounding effect of these important factors such as smoking or alcohol drinking regarding the association between benzodiazepine use and the risk of cancer.…”

“…Among these, 21 articles were excluded because of the following reasons: not relevant to our analysis (n 5 7), insufficient data (n 5 3), using psychotropic medication other than benzodiazepine (n 5 6), data from pre-existing cancer (n 5 3), using cancer mortality as a result, and using an acute biomarker as exposure. The remaining 21 studies including eighteen casecontrol studies 6,7,[13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] and four cohort studies 8,9,28,29 were included in the final analysis (the study by Kaufman et al 13 was considered as two separate case-control studies). All of the included articles were written in English.…”

“…Eight studies 6,7,13,23,[26][27][28] investigated breast cancer, three studies involved ovarian cancer, 14,19,21 two studies looked into colon cancer, 16,18 and five studies involved all types of cancer. 8,[26][27][28][29] They were conducted in the following countries: US (n 5 12), 6,7,[13][14][15]18,19,[21][22][23][24][25] Canada (n 5 2), 13,23 Sweden (n 5 3), 16,17,20 Denmark (n 5 1), 26 France (n 5 1), 29 and Taiwan (n 5 3). 9,27,28 Among 18 case-control studies, 13 studies 7,13,14,17,18,[20][21][22][23][24][25][26][27] were population-based studies, and five studies …”

Efeitos do diazepam sobre o crescimento do tumor ascítico de Ehrlich: envolvimento do Receptor Periférico para Benzodiazepínico (PBR) ou Proteína Translocadora (TSPO)

“…De qualquer forma, embora não tenham sido encontradas evidências epidemiológicas que correlacionem o uso de benzodiazepínicos e a incidência de tumores em humanos (ROSENBERG et al, 1995;HALAPY et al, 2006) vale lembrar que os benzodiazepínicos são amplamente utilizados pelas suas propriedades ansiolíticas e sedativas em pacientes portadores ou não de neoplasias (STIEFEL et al, 1999;SRIVASTAVA;WALSH, 2003) o que aponta para a necessidade de cuidado quando deste uso, que jamais deveria ser feito sem a devida prescrição médica. De fato, em nossos experimentos utilizamos uma dose de 3,0 mg/Kg, por via oral (uma dose de diazepam considerada ansiolítica) para camundongos (GRIEBEL et al, 2000;HAGENBUCH et al, 2006).…”

“…Embora o uso de benzodiazepínicos seja amplo e maior nos últimos anos, assim como o interesse da comunidade científica em estudar os efeitos de benzodiazepínicos sobre a proliferação de células tumorais, e em especial de ligantes de TSPO, poucos estudos têm sido realizados in vivo com os mesmos nos últimos anos. Neste sentido, dados epidemiológicos mostraram ausência de correlação positiva entre o uso de benzodiazepínicos e a incidência de câncer em humanos(ROSENBERG et al, 1995;HALAPY et al, 2006); entretanto, questões sobre os efeitos do diazepam sobre o crescimento tumoral in vivo ainda permanecem pouco elucidadas. O objetivo do presente estudo foi analisar o papel da TSPO nos efeitos in vivo induzidos pelo diazepam no crescimento do tumor de Ehrlich.…”